NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$73.55 +0.09 (+0.12 %)
(As of 01/17/2019 03:56 PM ET)
Previous Close$73.46
Today's Range$73.30 - $75.00
52-Week Range$46.25 - $76.99
Volume8,239 shs
Average Volume167,519 shs
Market Capitalization$3.14 billion
P/E Ratio-16.98
Dividend YieldN/A
Beta0.86
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.80 million
Book Value$5.82 per share

Profitability

Net Income$-140,040,000.00
Net Margins-38,569.44%

Miscellaneous

Employees137
Market Cap$3.14 billion
OptionableOptionable

Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Wednesday, November, 28th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.29. The biotechnology company had revenue of $0.02 million for the quarter, compared to analysts' expectations of $0.16 million. Ascendis Pharma A/S had a negative return on equity of 45.44% and a negative net margin of 38,569.44%. View Ascendis Pharma A/S's Earnings History.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Wednesday, March 27th 2019. View Earnings Estimates for Ascendis Pharma A/S.

What price target have analysts set for ASND?

9 equities research analysts have issued 12-month price targets for Ascendis Pharma A/S's shares. Their forecasts range from $60.00 to $88.00. On average, they expect Ascendis Pharma A/S's share price to reach $78.25 in the next year. This suggests a possible upside of 6.4% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S.

What is the consensus analysts' recommendation for Ascendis Pharma A/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S.

Has Ascendis Pharma A/S been receiving favorable news coverage?

News headlines about ASND stock have trended very positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ascendis Pharma A/S earned a coverage optimism score of 3.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days.

Who are some of Ascendis Pharma A/S's key competitors?

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the folowing people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Gen. Counsel (Age 47)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 58)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 44)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 49)
  • Dr. Harald Rau, Sr. VP & Chief Scientific Officer (Age 48)

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners acted as the underwriters for the IPO and Wells Fargo Securities was co-manager.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $73.55.

How big of a company is Ascendis Pharma A/S?

Ascendis Pharma A/S has a market capitalization of $3.14 billion and generates $1.80 million in revenue each year. The biotechnology company earns $-140,040,000.00 in net income (profit) each year or ($4.33) on an earnings per share basis. Ascendis Pharma A/S employs 137 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is http://www.ascendispharma.com.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  196 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  390
MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel